Drug intelligence / Profile preview

adebrelimab + TP + FP

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Adebrelimab + TP + FP is a combination immunotherapy-chemotherapy regimen currently being evaluated in Phase II clinical trials for the treatment of locally advanced unresectable esophageal squamous cell carcinoma (ESCC). The regimen consists of adebrelimab (SHR-1316), a humanized IgG4 monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1), combined with either a taxane-platinum (TP) doublet (paclitaxel or nab-paclitaxel plus carboplatin) or a fluoropyrimidine-platinum (FP) doublet (5-fluorouracil plus cisplatin). In the clinical trial setting (NCT05463107), patients receive induction therapy with adebrelimab and chemotherapy, followed by PET-CT-guided concurrent chemoradiotherapy (CCRT) and maintenance adebrelimab. The goal of this approach is to improve the conversion rate to resectability or achieve better local control in unresectable ESCC by leveraging the synergistic effects of PD-L1 inhibition and cytotoxic chemotherapy.

Brand names: Adely
Other names: adebrelimab plus chemotherapyadebrelimab + paclitaxel + carboplatinadebrelimab + fluorouracil + cisplatin

Targets

DNACD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)

Beyond the preview

Go deeper on adebrelimab + TP + FP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + TP + FP.

Explore the full profile